RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Raises Price Target to $16
RBC Capital analyst Brian Abrahams maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Sector Perform and raises the price target from $13 to $16.
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 175 companies set new 52-week highs.
JMP Securities Maintains Market Outperform on BioCryst Pharmaceuticals, Raises Price Target to $23
JMP Securities maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Market Outperform and raises the price target from $22 to $23.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Barclays Maintains Overweight on BioCryst Pharmaceuticals, Raises Price Target to $21
Barclays analyst Gena Wang maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Overweight and raises the price target from $20 to $21.
HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $30
HC Wainwright & Co. analyst Andrew Fein maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Buy and raises the price target from $18 to $30.
BioCryst Pharma Stock Heads Higher Thursday: Here’s Why
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results.
The company reported revenue of $50 million, with $28.5 million of net revenue coming from the company’s product Orladeyo.
Analyzing BioCryst Pharmaceuticals’s Unusual Options Activity
On Thursday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $16.95.
Biocryst Pharmaceuticals Q2 EPS $(0.24), Inline, ORLADEYO Net Revenue $28.5M
Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is unchanged from the same period last year.